匹多莫德联合伐昔洛韦治疗对复发性生殖器疱疹患者生化指标影响的临床研究

Influence of pidotimod joint valaciclovir treatment on the biochemical index of patients with recurrent genital herpes

目的:探讨匹多莫德联合伐昔洛韦治疗对复发性生殖器疱疹患者生化指标影响性,以期提高临床诊治水平。方法:选取2010年2月至2013年4月85例复发性生殖器疱疹患者为研究对象,分成两组,对照组42例,予伐昔洛韦治疗;观察组43例,加用匹多莫德治疗,观察治疗后在生化等指标变化情况。结果:疗效上,对照组治愈率14.28%、总有效率78.57%,观察组治愈率32.56%、总有效率93.02%,两者比较差异有统计学意义(P<0.05);治疗前在细胞因子IL-2、IL-12、TNF-γ和T淋巴细胞亚群CD4^+、CD3^+、CD8^+、CD4^+/CD8^+比较无差异性(P>0.05);治疗后和治疗前组内比较差异均有统计学意义(P<0.05),但观察组治疗后较对照组治疗后在以上指标上差异更有统计学意义(P<0.05)。结论:匹多莫德联合伐昔洛韦治疗复发性生殖器疱疹临床效果显著,治疗后能提高机体免疫力。

Objectives： To explore the influence of pidotimod joint valacyclovir therapy on the biochemical indicators of patients with recurrent genital herpes,in order to improve the clinical diagnosis and treatment.Methods： 85 patients with recurrent genital herpes from February 2010 to April 2013 were divided into two groups.42 cases in the control group received valacyclovir treatment,while 43 cases in the observation group received additional pidotimod after treatment. Changes in biochemical indicators after treatment were observed. Results： The cure rate and total efficiency in control group were 14. 28% and 78. 57%,while those in the observation group were32. 56% and 93. 02% respectively,with statistically significant difference（ P〈0. 05）. The cytokine IL- 2,IL-12,TNF- γ and T lymphocyte subsets CD4＋,CD3＋,CD8＋,CD4＋/ CD8＋before treatment showed no difference（ P〉0. 05）. Difference between before and after treatment was statistically significant in both groups（ P〈0. 05）,but compared with the control group,difference in biochemical indicators in observation group was of more statisti-cally significant difference（ P〈0. 05）. Conclusion： Pidotimod joint valaciclovir is of significant clinical effect in the treatment of recurrent genital herpes with improved immunity.